Skip to main content
HR 2883 117th Congress House

Stop Stalling Access to Affordable Medications

Official title: To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or … Show full official titleShow less

Official title: To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns, and for other purposes.

Introduced: April 28, 2021 Introduced by: Jeffries, Hakeem S. Democratic · New York See on congress.gov
Health Administrative remediesBusiness ethicsCivil actions and liabilityCompetition and antitrust
More subjectsShow fewer subjects
Department of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Licensing and registrationsPrescription drugsPublic participation and lobbying
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 29, 2021
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.
Sep 29, 2021
Committee Consideration and Mark-up Session Held.
Apr 28, 2021
Introduced in House
Apr 28, 2021
Referred to the House Committee on the Judiciary.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 29, 2021

Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.

 Plain-English summary Congressional Research Service

Stop Stalling Access to Affordable Medications

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

 Related & companion bills 1
  • S 1425 Related bill Stop STALLING Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 8
All 8 Democratic 1 Republican 2
R
Budd, Ted
North Carolina · Aug 12, 2022
Demings, Val
· Sep 28, 2021
Jackson Lee, Sheila
· Sep 28, 2021
 R
Owens, Burgess
Utah · Sep 24, 2021
Buck, Ken
· Apr 28, 2021
Cicilline, David
· Apr 28, 2021
MALONEY, CAROLYN
· Apr 28, 2021
 D
Nadler, Jerrold
New York · Apr 28, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2883: Stop Stalling Access to Affordable Medications. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2883/
MLA
"H.R. 2883: Stop Stalling Access to Affordable Medications." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2883/.
Bluebook (legal)
H.R. 2883, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2883/.
Markdown link
[H.R. 2883: Stop Stalling Access to Affordable Medications](https://openamerica.io/bill/117-HR-2883/)
Report a problem